1. Zimmer Biomet reported Q4 2024 sales of $2.023 billion, up 4.3%. 2. Net earnings for Q4 were $239.4 million, adjusted EPS was $2.31. 3. Full-year 2024 sales totaled $7.679 billion, an increase of 3.8%. 4. The company intends to expand beyond core orthopedics through acquisitions. 5. Projected revenue growth for 2025 anticipated between 1.0% to 3.5%.
Q4 growth and diversification plans signal potential for future revenue increases.
Strong financial results and strategic acquisitions can significantly influence market perception.
Diversifying into higher-growth segments may yield consistent future returns, similar to past acquisitions.
WARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024. The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over the prior year period, and an increase of 4.9% on a constant currency basis. Net sales for the full year were $7.679 billion, an increase of 3.8% over the prior year, and an increase of 4.8% on a constant currency basis. Net earnings for the fourth quarter were $239.4 million, or $462.4 million on an adjusted basis. For the full year, net earnings were $903.8 million, or $1.630 billion on an adjusted basis.
Diluted earnings per share were $1.20 for the fourth quarter, and adjusted diluted earnings per share were $2.31. Full-year diluted earnings per share were $4.43, and adjusted diluted earnings per share were $8.00.
"We are pleased with our fourth quarter results and strong performance to close 2024, delivering on our financial guidance and validating the solid work that the team is doing across the globe," said Ivan Tornos, Zimmer Biomet's President and Chief Executive Officer. "We have committed to diversifying our portfolio outside of core orthopedics and investing in attractive, higher-growth segments. Our recently announced agreement to acquire Paragon 28 marks a bold step towards executing on our diversification ambitions; once the transaction is closed, we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace."
Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release.
The following sales tables provide results by geography and product category for the three-month period and year ended December 31, 2024, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis.
| NET SALES - THREE MONTHS ENDED DECEMBER 31, 2024 | Constant | Net | Currency Sales % Change | % Change |
|---|---|---|---|---|
| United States $1,181.2 | 4.7% | 4.7% | ||
| International $842.0 | 3.7% | 5.2% | ||
| Total $2,023.2 | 4.3% | 4.9% |
The Company is providing the following full-year 2025 financial guidance:
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
For more information about our product portfolio and operations, visit www.zimmerbiomet.com.